Form 4: Mineralys Therapeutics Executive Exercises Stock Options
SEC Form 4 Filing
David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, exercised stock options on March 12, 2025.
Summary
- On March 12, 2025, David Malcom Rodman, the Chief Medical Officer of Mineralys Therapeutics, exercised stock options to acquire 6,349 shares of common stock at a price of $1.08 per share.
- Following the transaction, Rodman directly owns 170,869 shares of common stock and 115,880 derivative securities (stock options).
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing an executive's stock option exercise, which is neutral in sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives regarding their holdings of company stock.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it slightly increases the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| July 12, 2022 | Stock option vested with respect to 25% of the underlying shares. |
| March 12, 2025 | David Malcom Rodman exercised stock options. |
| March 13, 2025 | Date of signature for the Form 4 filing. |
| July 11, 2032 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.